Search

Your search keyword '"McCausland, Finnian"' showing total 49 results
Start Over Author "McCausland, Finnian"
49 results on '"McCausland, Finnian"'

2. Therapeutic Effects of Heart Failure Medical Therapies on Standardized Kidney Outcomes: Comprehensive Individual Participant–Level Analysis of 6 Randomized Clinical Trials

Author

Butt, Jawad H., McMurray, John J.V., Claggett, Brian L., Jhund, Pardeep S., Neuen, Brendon L., McCausland, Finnian R., Desai, Akshay S., Lam, Carolyn S.P., Pitt, Bertram, Pfeffer, Marc A., Packer, Milton, Beldhuis, Iris E., Voors, Adriaan A., Zannad, Faiez, Heerspink, Hiddo J.L., Solomon, Scott D., and Vaduganathan, Muthiah

Published
2024
Full Text
View/download PDF

4. Arrhythmia and Time of Day in Maintenance Hemodialysis: Secondary Analysis of the Monitoring in Dialysis Study

Author

Williamson, Don, Roy-Chaudhury, Prabir, Tumlin, James, Kher, Vijay, Reddy, Vikranth, Prakash, Kowdle Chandrasekhar, Charytan, David, Tiwari, Suresh Chandra, Pokhariyal, Saurabh, Podoll, Amber, Jasuja, Sanjeev, Walters, G. Leslie, Wangsnes, Kraig, Costea, Alexandru, Tombul, Selcuk, Singh, Balbir, Mishra, Brajesh, Yalagudri, Sachin, Shelke, Abhijeet, Narasimhan, Calambur, Karthigesan, A.M., Oomman, Abraham, Kumar, K.P. Pramod, Koplan, Bruce, Kaul, Upendra, Ghose, Tapan, Gupta, Ripen, Sethi, Arvind, Kumar, Nikhil, Hariharan, Ramesh, Sardana, Rajnish, Wahab, Arif, Khanna, N.N., Smith, Mark, Kamath, Suresh, Galphin, Claude, Sodhi, Puneet, Chakravarthy, Rajsekara, Budithi, Subba Rao, McCausland, Finnian, Gulati, Sanjeev, Dijoo, Munawer, Singh, Upendra, Jain, Salil, Saxena, Vishal, Sagar, Gaurav, Fissell, Rachel, Foley, Robert, Herzog, Charles A., McCullough, Peter, Rogers, John D., Tumlin, James A., Zimetbaum, Peter, Assar, Manish, Kremers, Mark, Winkelmayer, Wolfgang C., Soomro, Qandeel H., Koplan, Bruce A., Costea, Alexandru I., Williamson, Don E., McClure, Candace K., and Charytan, David M.

Published
2024
Full Text
View/download PDF

7. Abstract 12470: Sacubitril/Valsartan in Patients With Heart Failure and Deterioration of Kidney Function to Estimated Glomerular Filtration Rate Less Than 30ml/min/1.73m2: Insights From PARAGON-HF and PARADIGM-HF

Author

Chatur, Safia, Vaduganathan, Muthiah, Claggett, Brian L, McCausland, Finnian, Desai, Akshay S, Beldhuis, Iris, Rouleau, Jean L, Zile, Michael R, Packer, Milton, Pfeffer, Marc A, Lefkowitz, Martin P, McMurray, John J, and Solomon, Scott D

Published
2023
Full Text
View/download PDF

8. Implantable Loop Recorder Monitoring and the Incidence of Previously Unrecognized Atrial Fibrillation in Patients on Hemodialysis

Author

Williamson, Don, Roy-Chaudhury, Prabir, Tumlin, James, Kher, Vijay, Reddy, Vikranth, Chandrasekhar Prakash, Kowdle, Charytan, David, Tiwari, Suresh Chandra, Pokhariyal, Saurabh, Podoll, Amber, Jasuja, Sanjeev, Walters, G. Leslie, Wangsnes, Kraig, Costea, Alexandru, Tombul, Selcuk, Singh, Balbir, Mishra, Brajesh, Yalagudri, Sachin, Shelke, Abhijeet, Narasimhan, Calambur, Karthigesan, A.M., Oomman, Abraham, Kumar, K P Pramod, Koplan, Bruce, Kaul, Upendra, Ghose, Tapan, Gupta, Ripen, Sethi, Arvind, Kumar, Nikhil, Hariharan, Ramesh, Sardana, Rajnish, Wahab, Arif, Khanna, N.N., Smith, Mark, Kamath, Suresh, Galphin, Claude, Sodhi, Puneet, Chakravarthy, Rajsekara, Budithi, Subba Rao, McCausland, Finnian, Gulati, Sanjeev, Dijoo, Munawer, Singh, Upendra, Jain, Salil, Saxena, Vishal, Sagar, Gaurav, Fissell, Rachel, Foley, Robert, Herzog, Charles A., McCullough, Peter A., Rogers, John D., Tumlin, James A., Zimetbaum, Peter, Assar, Manish, Kremers, Mark, Winkelmayer, Wolfgang C., Koplan, Bruce A., Costea, Alexandru I., Williamson, Don E., and Charytan, David M.

Published
2022
Full Text
View/download PDF

9. Sacubitril/valsartan compared to ramipril in high-risk post-myocardial infarction patients stratified according to use of mineralocorticoid receptor antagonists:insight from the PARADISE MI trial

Author

Schou, Morten, Claggett, Brian, Miao, Zi Michael, Fernandez, Alberto, Filippatos, Gerasimos, Granger, Christopher, Jering, Karola, Maggioni, Aldo P., McCausland, Finnian, Villota, Julio Nuñez, Rouleau, Jean Lucien, Mody, Freny Vaghaiwalla, van der Meer, Peter, Vinereanu, Dragos, McGrath, Martina, Zhou, Yinong, Mann, Douglas L., Solomon, Scott D., Steg, Philippe Gabriel, Braunwald, Eugene, McMurray, John J.V., Pfeffer, Marc A., Køber, Lars, Schou, Morten, Claggett, Brian, Miao, Zi Michael, Fernandez, Alberto, Filippatos, Gerasimos, Granger, Christopher, Jering, Karola, Maggioni, Aldo P., McCausland, Finnian, Villota, Julio Nuñez, Rouleau, Jean Lucien, Mody, Freny Vaghaiwalla, van der Meer, Peter, Vinereanu, Dragos, McGrath, Martina, Zhou, Yinong, Mann, Douglas L., Solomon, Scott D., Steg, Philippe Gabriel, Braunwald, Eugene, McMurray, John J.V., Pfeffer, Marc A., and Køber, Lars

Abstract

Aim It is unknown whether safety and clinical endpoints by use of sacubitril/valsartan (an angiotensin receptor–neprilysin inhibitor [ARNI]) are affected by mineralocorticoid receptor antagonists (MRA) in high-risk myocardial infarction (MI) patients. The aim of this study was to examine whether MRA modifies safety and clinical endpoints by use of sacubitril/valsartan in patients with a MI and left ventricular systolic dysfunction (LVSD) and/or pulmonary congestion. Methods and results Patients (n = 5661) included in the PARADISE MI trial (Prospective ARNI vs. ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events After MI) were stratified according to MRA. Primary outcomes in this substudy were worsening heart failure or cardiovascular death. Safety was defined as symptomatic hypotension, hyperkalaemia >5.5 mmol/L, or permanent drug discontinuation. A total of 2338 patients (41%) were treated with MRA. Safety of ARNI compared to ramipril was not altered significantly by ± MRA, and both groups had similar increase in symptomatic hypotension with ARNI. In patients taking MRA, the risk of hyperkalaemia or permanent drug discontinuation was not significantly altered by ARNI (p > 0.05 for all comparisons). The effect of ARNI compared with ramipril was similar in those who were and were not taking MRA (hazard ratio [HR]MRA 0.96, 95% confidence interval [CI] 0.77–1.19 and HRMRA– 0.87, 95% CI 0.71–1.05, for the primary endpoint; p = 0.51 for interaction [Clinical Endpoint Committee adjudicated]); similar findings were observed if investigator-reported endpoints were evaluated (p = 0.61 for interaction). Conclusions Use of a MRA did not modify safety or clinical endpoints related to initiation of ARNI compared to ramipril in the post-MI setting in patients with LVSD and/or congestion., Aim: It is unknown whether safety and clinical endpoints by use of sacubitril/valsartan (an angiotensin receptor–neprilysin inhibitor [ARNI]) are affected by mineralocorticoid receptor antagonists (MRA) in high-risk myocardial infarction (MI) patients. The aim of this study was to examine whether MRA modifies safety and clinical endpoints by use of sacubitril/valsartan in patients with a MI and left ventricular systolic dysfunction (LVSD) and/or pulmonary congestion. Methods and results: Patients (n = 5661) included in the PARADISE MI trial (Prospective ARNI vs. ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events After MI) were stratified according to MRA. Primary outcomes in this substudy were worsening heart failure or cardiovascular death. Safety was defined as symptomatic hypotension, hyperkalaemia >5.5 mmol/L, or permanent drug discontinuation. A total of 2338 patients (41%) were treated with MRA. Safety of ARNI compared to ramipril was not altered significantly by ± MRA, and both groups had similar increase in symptomatic hypotension with ARNI. In patients taking MRA, the risk of hyperkalaemia or permanent drug discontinuation was not significantly altered by ARNI (p > 0.05 for all comparisons). The effect of ARNI compared with ramipril was similar in those who were and were not taking MRA (hazard ratio [HR]MRA 0.96, 95% confidence interval [CI] 0.77–1.19 and HRMRA– 0.87, 95% CI 0.71–1.05, for the primary endpoint; p = 0.51 for interaction [Clinical Endpoint Committee adjudicated]); similar findings were observed if investigator-reported endpoints were evaluated (p = 0.61 for interaction). Conclusions: Use of a MRA did not modify safety or clinical endpoints related to initiation of ARNI compared to ramipril in the post-MI setting in patients with LVSD and/or congestion.

Published
2024

13. Bidirectional Relationship Between Kidney Disease Progression and Cardiovascular Events in Type 2 Diabetes

Author

Neuen, Brendon L., Ostrominski, John W., Claggett, Brian, Beldhuis, Iris E., Chatur, Safia, McCausland, Finnian R., Badve, Sunil V., Arnott, Clare, Heerspink, Hiddo J.L., Jun, Min, Falster, Michael, de Oliveira Costa, Juliana, Pollock, Carol, Jardine, Meg J., Mahaffey, Kenneth W., Perkovic, Vlado, Solomon, Scott D., and Vaduganathan, Muthiah

Published
2024
Full Text
View/download PDF

15. Sacubitril/valsartan compared to ramipril in high‐risk post‐myocardial infarction patients stratified according to use of mineralocorticoid receptor antagonists: insight from the PARADISE MI trial

Author

Schou, Morten, primary, Claggett, Brian, additional, Miao, Zi Michael, additional, Fernandez, Alberto, additional, Filippatos, Gerasimos, additional, Granger, Christopher, additional, Jering, Karola, additional, Maggioni, Aldo P., additional, McCausland, Finnian, additional, Villota, Julio Nuñez, additional, Rouleau, Jean‐Lucien, additional, Mody, Freny Vaghaiwalla, additional, van der Meer, Peter, additional, Vinereanu, Dragos, additional, McGrath, Martina, additional, Zhou, Yinong, additional, Mann, Douglas L., additional, Solomon, Scott D., additional, Steg, Philippe Gabriel, additional, Braunwald, Eugene, additional, McMurray, John J.V., additional, Pfeffer, Marc A., additional, and Køber, Lars, additional

Published
2023
Full Text
View/download PDF

16. Abstract 12470: Sacubitril/Valsartan in Patients With Heart Failure and Deterioration of Kidney Function to Estimated Glomerular Filtration Rate Less Than 30ml/min/1.73m 2 : Insights From PARAGON-HF and PARADIGM-HF

Author

Chatur, Safia, primary, Vaduganathan, Muthiah, additional, Claggett, Brian L, additional, McCausland, Finnian, additional, Desai, Akshay S, additional, Beldhuis, Iris, additional, Rouleau, Jean L, additional, Zile, Michael R, additional, Packer, Milton, additional, Pfeffer, Marc A, additional, Lefkowitz, Martin P, additional, McMurray, John J, additional, and Solomon, Scott D, additional

Published
2023
Full Text
View/download PDF

18. Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: A joint analysis of randomized controlled clinical trials

Author

Heerspink, Hiddo J. L., primary, Vart, Priya, additional, Jongs, Niels, additional, Neuen, Brendon L., additional, Bakris, George, additional, Claggett, Brian, additional, Vaduganathan, Muthiah, additional, McCausland, Finnian, additional, Docherty, Kieran F., additional, Jhund, Pardeep S., additional, Solomon, Scott D., additional, Perkovic, Vlado, additional, and McMurray, John J. V., additional

Published
2023
Full Text
View/download PDF

19. Sacubitril/valsartan compared to ramipril in high‐risk post‐myocardial infarction patients stratified according to use of mineralocorticoid receptor antagonists: Insight from the PARADISE MI trial.

Author

Schou, Morten, Claggett, Brian, Miao, Zi Michael, Fernandez, Alberto, Filippatos, Gerasimos, Granger, Christopher, Jering, Karola, Maggioni, Aldo P., McCausland, Finnian, Villota, Julio Nuñez, Rouleau, Jean‐Lucien, Mody, Freny Vaghaiwalla, van der Meer, Peter, Vinereanu, Dragos, McGrath, Martina, Zhou, Yinong, Mann, Douglas L., Solomon, Scott D., Steg, Philippe Gabriel, and Braunwald, Eugene

Subjects
MINERALOCORTICOID receptors, VALSARTAN, ENTRESTO, RAMIPRIL, INFARCTION
Abstract

Aim: It is unknown whether safety and clinical endpoints by use of sacubitril/valsartan (an angiotensin receptor–neprilysin inhibitor [ARNI]) are affected by mineralocorticoid receptor antagonists (MRA) in high‐risk myocardial infarction (MI) patients. The aim of this study was to examine whether MRA modifies safety and clinical endpoints by use of sacubitril/valsartan in patients with a MI and left ventricular systolic dysfunction (LVSD) and/or pulmonary congestion. Methods and results: Patients (n = 5661) included in the PARADISE MI trial (Prospective ARNI vs. ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events After MI) were stratified according to MRA. Primary outcomes in this substudy were worsening heart failure or cardiovascular death. Safety was defined as symptomatic hypotension, hyperkalaemia >5.5 mmol/L, or permanent drug discontinuation. A total of 2338 patients (41%) were treated with MRA. Safety of ARNI compared to ramipril was not altered significantly by ± MRA, and both groups had similar increase in symptomatic hypotension with ARNI. In patients taking MRA, the risk of hyperkalaemia or permanent drug discontinuation was not significantly altered by ARNI (p > 0.05 for all comparisons). The effect of ARNI compared with ramipril was similar in those who were and were not taking MRA (hazard ratio [HR]MRA 0.96, 95% confidence interval [CI] 0.77–1.19 and HRMRA– 0.87, 95% CI 0.71–1.05, for the primary endpoint; p = 0.51 for interaction [Clinical Endpoint Committee adjudicated]); similar findings were observed if investigator‐reported endpoints were evaluated (p = 0.61 for interaction). Conclusions: Use of a MRA did not modify safety or clinical endpoints related to initiation of ARNI compared to ramipril in the post‐MI setting in patients with LVSD and/or congestion. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

22. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials

Author

Baigent, Colin, primary, Emberson, JonathanR., additional, Haynes, Richard, additional, Herrington, William G., additional, Judge, Parminder, additional, Landray, Martin J., additional, Mayne, Kaitlin J., additional, Ng, Sarah Y.A., additional, Preiss, David, additional, Roddick, Alistair J., additional, Staplin, Natalie, additional, Zhu, Doreen, additional, Anker, Stefan D., additional, Bhatt, Deepak L., additional, Brueckmann, Martina, additional, Butler, Javed, additional, Cherney, David Z.I., additional, Green, Jennifer B., additional, Hauske, Sibylle J., additional, Heerspink, Hiddo J.L., additional, Inzucchi, Silvio E., additional, Jardine, Meg J., additional, Liu, Chih-Chin, additional, Mahaffey, Kenneth W., additional, McCausland, Finnian R., additional, McGuire, Darren K., additional, McMurray, John J.V., additional, Neal, Bruce, additional, Neuen, Brendon L., additional, Packer, Milton, additional, Perkovic, Vlado, additional, Sabatine, Marc S., additional, Solomon, Scott D., additional, Vaduganathan, Muthiah, additional, Wanner, Christoph, additional, Wheeler, David C., additional, Wiviott, Stephen D., additional, and Zannad, Faiez, additional

Published
2022
Full Text
View/download PDF

24. Analysis of on-treatment cancer safety events with daprodustat versus conventional erythropoiesis-stimulating agents—post hoc analyses of the ASCEND-ND and ASCEND-D trials.

Author

Singh, Ajay K, McCausland, Finnian R, Claggett, Brian L, Wanner, Christoph, Wiecek, Andrzej, Atkins, Michael B, Carroll, Kevin, Perkovic, Vlado, McMurray, John J V, Wittes, Janet, Snapinn, Steven, Blackorby, Allison, Meadowcroft, Amy, Barker, Tara, DiMino, Tara, Mallett, Stephen, Cobitz, Alexander R, and Solomon, Scott D

Subjects
*HEMODIALYSIS patients, *DISEASE risk factors
Abstract

Background The prespecified on-treatment analysis of ASCEND-ND (NCT02876835) raised concerns about a higher relative risk of cancer-related adverse events (AEs) with daprodustat vs darbepoetin in patients with anaemia of CKD. This concern was not observed in dialysis patients in ASCEND-D (NCT02879305). Methods ASCEND-ND randomized 3872 patients to daprodustat or darbepoetin. ASCEND-D randomized 2964 patients to daprodustat or conventional erythropoiesis-stimulating agents (ESAs). In both studies ESA comparators used different dosing intervals (3/week, 1/week, every 2 or every 4 weeks). The prespecified on-treatment approach examined relative risks for cancer AEs up to the last dose date + 1 day. In these analyses, owing to different dosing intervals between arms, Cox models were used to estimate the daprodustat effect by various follow-up periods (censoring at last dose date, last dose date + dosing intervals, or end of study). Results In ASCEND-ND, the safety of daprodustat vs darbepoetin on cancer-related AEs depended on the duration of follow-up after last dose date: hazard ratio (HR) 1.04 [95% confidence interval (CI) 0.77, 1.40] at end of study [HR 1.12 (95% CI 0.81, 1.56) for last dose date + dosing interval; HR 1.50 (95% CI 1.04, 2.15) for last dose date + 1 day]. In ASCEND-D, no excess risk of cancer-related AEs was observed with any model examined. Conclusions Prespecified on-treatment analyses for cancer-related AEs appeared to result in biased risk estimates in ASCEND-ND by preferentially under-counting events from patients assigned to darbepoetin. Analyses accounting for longer darbepoetin dosing intervals, or extending follow-up, resulted in attenuation of effect estimates towards neutrality, similar to ASCEND-D, where ESA comparator dosing intervals are closer to daprodustat. Trial registration The ASCEND-ND trial is registered with ClinicalTrials.gov (NCT02876835); the ASCEND-D trial is registered with ClinicalTrials.gov (NCT02879305). [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

25. Longitudinal trajectories in renal function before and after heart failure hospitalization among patients with HFpEF in the PARAGON‐HF trial

Author

Chatur, Safia, Vaduganathan, Muthiah, Peikert, Alexander, Claggett, Brian L, McCausland, Finnian R., Skali, Hicham, Pfeffer, Marc A., Beldhuis, Iris E, Kober, Lars, Seferovic, Petar, Lefkowitz, Martin, McMurray, John J.V., and Solomon, Scott D.

Abstract

Aims: \ud Worsening renal function may impact long-term outcomes in heart failure (HF). However, little is known about the longitudinal trajectories in renal function in relation to the HF hospitalization or how this high-risk clinical event impacts renal outcomes.\ud \ud Methods and Results: \ud In PARAGON-HF, we evaluated the association between recency of prior HF hospitalization (occurring pre-randomization) and subsequent first renal composite outcome: (1) time to ≥50% decline in eGFR ; (2) development of end stage renal disease (ESRD); or (3) death attributable to renal causes. 2,306 (48.1%) patients had a history of prior HF hospitalization. Incident rates of the renal outcome were highest in those most recently hospitalized and decreased with longer time from last hospitalization. Treatment effect on the renal outcome of sacubitril/valsartan vs. valsartan was similar between patients with (HR 0.43; 95% CI: 0.26 to 0.75) and without (HR 0.63; 95% CI: 0.33 to 1.18; Pinteraction = 0.39) a prior history of HF hospitalization and appeared consistent regardless of timing of prior hospitalization for HF (Pinteraction =0.39). Serial eGFR measurements leading up to and after a HF hospitalization (occurring during the study period) and estimated eGFR trajectories using repeated measures regression models with restricted cubic splines were also examined. Patients experiencing a post-randomization HF hospitalization had a significant decline in eGFR prior to hospitalization while patients without HF hospitalization experienced a relatively stable eGFR trajectory (p

Published
2022

26. Longitudinal trajectories in renal function before and after heart failure hospitalization among patients with heart failure with preserved ejection fraction in the PARAGON‐HF trial

Author

Chatur, Safia, primary, Vaduganathan, Muthiah, additional, Peikert, Alexander, additional, Claggett, Brian L., additional, McCausland, Finnian R., additional, Skali, Hicham, additional, Pfeffer, Marc A., additional, Beldhuis, Iris E., additional, Kober, Lars, additional, Seferovic, Petar, additional, Lefkowitz, Martin, additional, McMurray, John J.V., additional, and Solomon, Scott D., additional

Published
2022
Full Text
View/download PDF

27. Longitudinal trajectories in renal function before and after heart failure hospitalization among patients with heart failure with preserved ejection fraction in the PARAGON-HF trial

Author

Chatur, Safia, Vaduganathan, Muthiah, Peikert, Alexander, Claggett, Brian L., McCausland, Finnian R., Skali, Hicham, Pfeffer, Marc A., Beldhuis, Iris E., Kober, Lars, Seferovic, Petar, Lefkowitz, Martin, McMurray, John J.V., Solomon, Scott D., Chatur, Safia, Vaduganathan, Muthiah, Peikert, Alexander, Claggett, Brian L., McCausland, Finnian R., Skali, Hicham, Pfeffer, Marc A., Beldhuis, Iris E., Kober, Lars, Seferovic, Petar, Lefkowitz, Martin, McMurray, John J.V., and Solomon, Scott D.

Abstract

Aims: Worsening renal function may impact long-term outcomes in heart failure (HF). However, little is known about the longitudinal trajectories in renal function in relation to HF hospitalization or how this high-risk clinical event impacts renal outcomes. Methods and results: In PARAGON-HF, we evaluated the association between recency of prior HF hospitalization (occurring pre-randomization) and subsequent first renal composite outcome: (i) time to ≥50% decline in estimated glomerular filtration rate (eGFR); (ii) development of end-stage renal disease; or (iii) death attributable to renal causes. A total of 2306 (48.1%) patients had a history of prior HF hospitalization. Incident rates of the renal outcome were highest in those most recently hospitalized and decreased with longer time from last hospitalization. Treatment effect on the renal outcome of sacubitril/valsartan versus valsartan was similar between patients with (hazard ratio [HR] 0.43; 95% confidence interval [CI] 0.24–0.76) and without (HR 0.63; 95% CI: 0.33–1.18; pinteraction = 0.39) a prior history of HF hospitalization and appeared consistent regardless of timing of prior hospitalization for HF (pinteraction = 0.39). Serial eGFR measurements leading up to and after a HF hospitalization (occurring during the study period) and estimated eGFR trajectories using repeated measures regression models with restricted cubic splines were also examined. Patients experiencing a post-randomization HF hospitalization had a significant decline in eGFR prior to hospitalization while patients without HF hospitalization experienced a relatively stable eGFR trajectory (p < 0.001). A change in the rate of decline of eGFR trajectory was observed 12 months preceding a HF hospitalization, and continued in the post-discharge window to 12 months following hospitalization. Conclusions: Heart failure hospitalization denotes increased risk for kidney disease progression which continues following rec

Published
2022

28. EFFECTS OF SACUBITRIL/VALSARTAN VERSUS VALSARTAN ON RENAL FUNCTION IN PATIENTS WITH TYPE 2 DIABETES AND HEART FAILURE WITH PRESERVED EJECTION FRACTION: PARAGON-HF

Author

Peikert, Alexander, primary, Vaduganathan, Muthiah, additional, McCausland, Finnian, additional, Claggett, Brian, additional, Chatur, Safia, additional, Packer, Milton, additional, Pfeffer, Marc A., additional, Zannad, Faiez, additional, Lefkowitz, Martin, additional, Pieske, Burkert Mathias, additional, Düngen, Hans-Dirk, additional, McMurray, John J.V., additional, and Solomon, Scott D., additional

Published
2022
Full Text
View/download PDF

29. Implantable Loop Recorder Monitoring and the Incidence of Previously Unrecognized Atrial Fibrillation in Patients on Hemodialysis

Author

Koplan, Bruce A., primary, Winkelmayer, Wolfgang C., additional, Costea, Alexandru I., additional, Roy-Chaudhury, Prabir, additional, Tumlin, James A., additional, Kher, Vijay, additional, Williamson, Don E., additional, Pokhariyal, Saurabh, additional, Charytan, David M., additional, Williamson, Don, additional, Tumlin, James, additional, Reddy, Vikranth, additional, Chandrasekhar Prakash, Kowdle, additional, Charytan, David, additional, Tiwari, Suresh Chandra, additional, Podoll, Amber, additional, Jasuja, Sanjeev, additional, Walters, G. Leslie, additional, Wangsnes, Kraig, additional, Costea, Alexandru, additional, Tombul, Selcuk, additional, Singh, Balbir, additional, Mishra, Brajesh, additional, Yalagudri, Sachin, additional, Shelke, Abhijeet, additional, Narasimhan, Calambur, additional, Karthigesan, A.M., additional, Oomman, Abraham, additional, Kumar, K P Pramod, additional, Koplan, Bruce, additional, Kaul, Upendra, additional, Ghose, Tapan, additional, Gupta, Ripen, additional, Sethi, Arvind, additional, Kumar, Nikhil, additional, Hariharan, Ramesh, additional, Sardana, Rajnish, additional, Wahab, Arif, additional, Khanna, N.N., additional, Smith, Mark, additional, Kamath, Suresh, additional, Galphin, Claude, additional, Sodhi, Puneet, additional, Chakravarthy, Rajsekara, additional, Budithi, Subba Rao, additional, McCausland, Finnian, additional, Gulati, Sanjeev, additional, Dijoo, Munawer, additional, Singh, Upendra, additional, Jain, Salil, additional, Saxena, Vishal, additional, Sagar, Gaurav, additional, Fissell, Rachel, additional, Foley, Robert, additional, Herzog, Charles A., additional, McCullough, Peter A., additional, Rogers, John D., additional, Zimetbaum, Peter, additional, Assar, Manish, additional, and Kremers, Mark, additional

Published
2022
Full Text
View/download PDF

31. Challenges of Cardio-Kidney Composite Outcomes in Large-Scale Clinical Trials

Author

Patel, Ravi B., primary, Ter Maaten, Jozine M., additional, Ferreira, João Pedro, additional, McCausland, Finnian R., additional, Shah, Sanjiv J., additional, Rossignol, Patrick, additional, Solomon, Scott D., additional, Vaduganathan, Muthiah, additional, Packer, Milton, additional, Thompson, Aliza, additional, Stockbridge, Norman, additional, and Zannad, Faiez, additional

Published
2021
Full Text
View/download PDF

32. Filter Clotting with Continuous Renal Replacement Therapy in COVID-19

Author

Rosovsky, Rachel P., primary, Endres, Paul, additional, Zhao, Soophia H, additional, Krinsky, Scott, additional, Percy, Shananssa G, additional, Kamal, Omer, additional, Roberts, Russel J., additional, Lopez, Natasha, additional, Sise, Meghan E, additional, Steele, David J, additional, Lundquist, Andrew L, additional, Rhee, Eugene P, additional, Hibbert, Kathryn A, additional, Hardin, Charles C, additional, McCausland, Finnian R, additional, Czarnecki, Peter G., additional, Mutter, Walter P, additional, Tolkoff-Rubin, Nina E, additional, and Allegretti, Andrew S, additional

Published
2020
Full Text
View/download PDF

33. MODE OF DEATH IN PATIENTS WITH HEART FAILURE AND LEFT VENTRICULAR EJECTION FRACTION≥45%: INSIGHTS FROM PARAGON-HF

Author

Desai, Akshay S., primary, Cleland, John, additional, Vaduganathan, Muthiah, additional, Claggett, Brian, additional, Barkoudah, Ebrahim, additional, Finn, Peter V., additional, McCausland, Finnian, additional, Yilmaz, Mehmet B., additional, Lefkowitz, Martin, additional, Shi, Victor, additional, Pfeffer, Marc A., additional, McMurray, John, additional, and Solomon, Scott D., additional

Published
2020
Full Text
View/download PDF

34. Determinants and Outcomes Associated With Urinary Calcium Excretion in Chronic Kidney Disease.

Author

Jing Liu, Tio, Maria Clarissa, Verma, Ashish, Schmidt, Insa M., Ilori, Titilayo O., Knauf, Felix, McCausland, Finnian R., and Waikar, Sushrut S.

Subjects
CHRONIC kidney failure, CALCIUM metabolism, EXCRETION, CALCIUM, ARTERIAL calcification, GLOMERULAR filtration rate
Abstract

Context: Abnormalities in calcium metabolism are common in chronic kidney disease (CKD). Diminished urinary calcium excretion may promote vascular calcification and increased urinary calcium excretion may lead to nephrolithiasis and nephrocalcinosis, conditions associated with CKD. Objective: To study predictors of urinary calcium excretion and its association with adverse clinical outcomes in CKD. Design, Setting and Patients: This study assessed 3768 nondialysis participants in the Chronic Renal Insufficiency Cohort study from April 2003 to September 2008. Participants were followed up to October 2018. Exposure: Clinically plausible predictors of urinary calcium excretion and 24-h urinary calcium excretion at baseline. Main Outcome Measures: Urinary calcium excretion; incident end stage kidney disease (ESKD), CKD progression [50% estimated glomerular filtration rate (eGFR) decline or incident ESKD], all-cause mortality, and atherosclerotic cardiovascular disease events. Results: eGFR was positive correlated with 24-h urinary calcium excretion. The variables most strongly associated with 24-h urinary calcium excretion in males and females were 24-h urinary sodium (ß = 0.19 and 0.28, respectively), serum parathyroid hormone (ß = -0.22 and -0.20, respectively), loop diuretics (ß = 0.36 and 0.26, respectively), thiazide diuretics (ß = -0.49 and -0.53, respectively), and self-identified black race (ß = -0.23 and -0.27, respectively). Lower urinary calcium excretion was associated with greater risks of adverse outcomes, but these associations were greatly attenuated or nullified after adjustment for baseline eGFR. Conclusion: Urinary calcium excretion is markedly lower in individuals with CKD compared to the general population. Determinants of urinary calcium excretion differed between sexes and levels of CKD. Associations between urinary calcium excretion and adverse clinical events were substantially confounded by eGFR. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

35. Timing of referral for vascular access placement: A systematic review

Author

Murad, Hassan M., Sidawy, Anton N., Elamin, Mohamed B., Rizvi, Adnan Z., Flynn, David N., McCausland, Finnian R., McGrath, Martina M., Vo, Danny H., El-Zoghby, Ziad, Casey, Edward T., Duncan, Audra A., Tracz, Michal J., Erwin, Patricia J., and Montori, Victor M.

Published
2008

38. CREATININE VERSUS CYSTATIN C TO ESTIMATE GLOMERULAR FILTRATION RATE IN ADULTS WITH CONGENITAL HEART DISEASE

Author

Rajpal, Saurabh, primary, Carazo, Matthew, additional, Singh, Michael, additional, Dimopoulos, Konstantinos, additional, Estrada, David Alejandro Cardona, additional, Waikar, Sushrut, additional, McCausland, Finnian, additional, Elantably, Ahmed, additional, Veldtman, Gruschen, additional, Grewal, Jasmine, additional, Loukas, Brittani, additional, Gray, Catherine, additional, and Opotowsky, Alexander, additional

Published
2019
Full Text
View/download PDF

39. Primary outcomes of the Monitoring in Dialysis Study indicate that clinically significant arrhythmias are common in hemodialysis patients and related to dialytic cycle

Author

Roy-Chaudhury, Prabir, primary, Tumlin, Jim A., additional, Koplan, Bruce A., additional, Costea, Alexandru I., additional, Kher, Vijay, additional, Williamson, Don, additional, Pokhariyal, Saurabh, additional, Charytan, David M., additional, Roy-Chaudhury, Prabir, additional, Tumlin, James, additional, Reddy, Vikranth, additional, Prakash, Kowdle Chandrasekhar, additional, Charytan, David, additional, Tiwari, Suresh Chandra, additional, Podoll, Amber, additional, Jasuja, Sanjeev, additional, Walters, G. Leslie, additional, Wangsnes, Kraig, additional, Costea, Alexandru, additional, Tombul, Selcuk, additional, Singh, Balbir, additional, Mishra, Brajesh, additional, Yalagudri, Sachin, additional, Shelke, Abhijeet, additional, Narasimhan, Calambur, additional, Karthigesan, A.M., additional, Oomman, Abraham, additional, Kumar, K.P. Pramod, additional, Koplan, Bruce, additional, Kaul, Upendra, additional, Ghose, Tapan, additional, Gupta, Ripen, additional, Sethi, Arvind, additional, Kumar, Nikhil, additional, Hariharan, Ramesh, additional, Sardana, Rajnish, additional, Wahab, Arif, additional, Khanna, N.N., additional, Smith, Mark, additional, Kamath, Suresh, additional, Galphin, Claude, additional, Sodhi, Puneet, additional, Chakravarthy, Rajsekara, additional, Budithi, Subba Rao, additional, McCausland, Finnian, additional, Gulati, Sanjeev, additional, Dijoo, Munawer, additional, Singh, Upendra, additional, Jain, Salil, additional, Saxena, Vishal, additional, Sagar, Gaurav, additional, Fissell, Rachel, additional, Foley, Robert, additional, Herzog, Charles A., additional, McCullough, Peter, additional, Rogers, John D., additional, Tumlin, James A., additional, Zimetbaum, Peter, additional, Assar, Manish, additional, Kremers, Mark, additional, and Winkelmayer, Wolfgang C., additional

Published
2018
Full Text
View/download PDF

40. Comparison of Urine Output among Patients Treated with More Intensive Versus Less Intensive RRT: Results from the Acute Renal Failure Trial Network Study

Author

Palevsky, Paul M., Betensky, Rebecca A., McCausland, Finnian R., Asafu-Adjei, Josephine, and Waikar, Sushrut S.

Subjects
urologic and male genital diseases, female genital diseases and pregnancy complications
Abstract

Intensive RRT may have adverse effects that account for the absence of benefit observed in randomized trials of more intensive versus less intensive RRT. We wished to determine the association of more intensive RRT with changes in urine output as a marker of worsening residual renal function in critically ill patients with severe AKI.

Published
2016
Full Text
View/download PDF

48. Renal Allograft Rupture: A Strategy for Graft Preservation

Author

McCausland, Finnian R., primary, Varma, Manish C., additional, Goes, Nelson B., additional, Heher, Eliot C., additional, Markmann, James F., additional, Cosimi, A. Benedict, additional, Elias, Nahel, additional, Ko, Dicken S., additional, Kawai, Tatsuo, additional, Smith, R. Neal, additional, and Rubin, Mario F., additional

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results